text:
ReviewGist App
Read reviews on the go.
'the browser of the phone is very good.'
'No Wi-Fi.'
'The photopgraphy experience is average'
'built-in answer / end call'
'The handset is designed for one-handed picture taking and features steady-grip materials and an in the box wrist strap, perfect for an active lifestyle.'
'the flash is not Xenon, either PhotoFlash (as in C902), but is simply a dual LED'
'Navigator software is trial version'
'Sound in the earpiece is somewhat muffled, a probable consequence of the materials used to reinforce the vulnerable parts of the splash and dust resistant phone.'
'Use my unique Cell Phone Chooser Test'
'It will be available in two colors: noble blue and golden ivory.'
'In order to make it definitely different, the design was almost drastically changed.'
'a proper xenon-gas-filled flash to provide a bright burst of flash to brighten up your subject.'
'We were rather underwhelmed by the keys, which feel too small and too far apart, making texting less enjoyable than it could be.'
'rather steep price'
'This whole combination, together with the colors of the lights, looks very … strange.'
'the navigation pad can be somewhat awkward to
on the internal ring surrounding the central select button.'
'some disguise it is: with this slim slider almost everything is staked on design.'
'small flip phone'
'just use the phone as a portable photo album to make sure that your memories are always with you.'
'We have mixed feelings about the Z310i.'
'Stop Unbuntu Beeping.'
'VGA camera built-in'
'Switching between the cell phone and the music player is seamless, as music automatically stops when you receive a call.'
'you can enjoy the full stereo power of the phone's media player completely wire-free.'
'the camera control is usable only when the phone is open.'
'It also lacks stereo speakers'
'This page has a good deal of resources on that phone.'
'we didn't quite like the small and pixelated (128 x 160-pixel) color LCD screen on the inside of the phone'
'Unfortunately the phone does not have a 3.5mm headphone jack, so you'll need to listen to tunes using the supplied headphones.'
'The soft keys in the upper part are too small and the clamshell construction makes hard the access to them.'
'Sony Ericsson chose to cast the W850i in a very trendy slider design.'
'it's a touch chunky at 21mm thick and sits heavily in the pocket, though it feels exceptionally robust'
'Videos were a little disappointing though as they looked a bit choppy.'
ReviewGist helps you find the best products to buy by making sense of online reviews.
We are currently aggregating 372,308 reviews
covering over 29,324 products. See what the press says about ReviewGist here.
© 2007-15 ReviewGist.com. All Rights Reserved.


text: Meta Battle Subway PokeBase - Pokemon Q&A Login Register All Activity Questions Unanswered Tags Users Ask a Question Rules Chat Simple and Helping Hand? 0 votes Does Helping Hand get the help of Simple? (I do know that Audino can pull this off with Simple Beam.) helping-hand simple asked Aug 4, 2011 by Kyogreruler Please log in or register to add a comment. Please log in or register to answer this question. 1 Answer 0 votes Best answer No, Simple only affects stat changes like growl which are permanent until you switch, are hazed, ect. answered Aug 4, 2011 by Halcyonic Falcon Please log in or register to add a comment. Related questions Does Helping Hand Boost Attacking and Special Attacking Moves? Helping Hand in Triples? Does helping hand affect the power of Mega kangaskan's second move of the turn? Will Helping Hand affect Flash Fire? Does Helping Hand increase the BP of Natural Gift? Do the effects of Helping Hand wear off? Does Helping Hand boost the power of Nature Power? Help with Helping Hand?? Useful Meta Posts How to change your username How to add a user avatar Why was my post hidden? The points system Question etiquette Flags vs Downvotes Anime FAQ

subset: commoncrawl


text:
man's portrait by MartaSyrkoWatch
©2012-2015 MartaSyrko
yes, yes he should be a rockstar. nice
such a handsome man.
I thought first it is Eric Northman...
Nice portrait
Nice portrait
perfect man
thats great work!
Great photo as always I love B&W photos.
Great black and white balance. Not too much gray, but not overly contrasted either. I like the look you've captured. Like his mind is far off somewhere. Also, he's handsome! That doesn't hurt. Haha.


text:
realmagick.com The shrine of knowledge.
Venom Band Biography
A selection of articles related to venom band biography.
Original articles from our library related to the Venom Band Biography. See Table of Contents for further available material (downloadable resources) on Venom Band Biography.
- Planes of Existence
- As shown in this diagram, planes of existence should not, as they commonly are, be thought of as discreet states but rather as a continuous scale. As we distinguish between body, mind and soul, we must equally distinguish between physical, mental, and...
Parapsychology >> Astral Projection
- Mythic Heroes of Celtic Ireland
- The Celtic mythology of Ireland is best summarized as consisting of four broad cycles. This month's article deals with mythic Celtic mortals, figures who populate the stories in the second and third cycles below. Four Cycles of Irish Mythology Foundation...
Saga of Times Past >> Legend and Prehistory
- Trance-formation (The Cosmic Tao of the Sexes)
- The purest outpouring of love between the sexes, is as a miniature super-nova of ecstatic union. Reciprocating pleasure becomes the engine that feeds the fires of passion. Passion becomes dynamic fuel for love. It is an engine that runs with the force of a...
Body Mysteries >> Yoga
- King James Bible: John, Chapter 18
- Chapter 18 18:1 When Jesus had spoken these words, he went forth with his disciples over the brook Cedron, where was a garden, into the which he entered, and his disciples. 18:2 And Judas also, which betrayed him, knew the place: for Jesus ofttimes resorted...
New Testament >> John
- King James Bible: Acts, Chapter 10
- Chapter 10 10:1 There was a certain man in Caesarea called Cornelius, a centurion of the band called the Italian band, 10:2 A devout man, and one that feared God with all his house, which gave much alms to the people, and prayed to God alway. 10:3 He saw in a...
New Testament >> The Acts
- Loki
- Norse God of Mischief, Trickery. Divine Catalyst, Breaker of Stagnation, Force for change. Giant brother of Odin. Loki wavers between a weal-bringing culture-hero/trickster and a woe-bringing destroyer. He is responsible for getting the gods most of their...
Deities & Heros >> Nordic & Germanic
Venom Band Biography is described in multiple online sources, as addition to our editors' articles, see section below for printable documents, Venom Band Biography books and related discussion.
Suggested Pdf Resources
- Monash Venom Group Group Head A/Professor Wayne Hodgson
- Monash Venom Group. Group Head. A/Professor Wayne Hodgson.
- www.med.monash.edu.au
- Inflammatory effects of snake venom metalloproteinases
- mammalian matrix metalloproteinases (MMP) and members of ADAMs (a disintegrin and metalloproteinase) group.
- www.scielo.br
- Interisland Mutation of a Novel Phospholipase A2 from Trimeresurus
- flavoviridis Venom and Evolution of Crotalinae Group II Phospholipases A2. Takahito Chijiwa,1 Sachiko . Biolyte 3/10 (Bio-Rad Japan, Tokyo).
- www.springerlink.com
- Structure and Phylogeny of the Venom Group I Phospholipase A2
- besides being the very first report on any venom group I PLA2 gene, constitutes the missing link in .
- mbe.oxfordjournals.org
- ARTICLE IN PRESS Cloning, characterization and phylogenetic
- members of three major venom families from a single specimen of Walterinnesia ..
- ntur.lib.ntu.edu.tw
Suggested Web Resources
- Venom (band) - Wikipedia, the free encyclopedia
- Members. Main article: List of Venom band members. [edit.
- en.wikipedia.org
- The Biography of Venom. Actually Venom started as a 5 member band called Oberon .
- www.sing365.com
- Venom Biography by swedish legion Mike Eriksson
- VENOM BIOGRAPHY by Mike Eriksson.
- www.venom.nu
- Venom | Biography
- Venom's lyrics often featured Satanic references, and the band members took on new stage names.
- www.lyricsfreak.com
- Venom Band Biography | RM.com ®
- Venom Band Biography articles, reference materials. Need more on Venom Band Biography?
- www.realmagick.com
Great care has been taken to prepare the information on this page. Elements of the content come from factual and lexical knowledge databases, realmagick.com library and third-party sources. We appreciate your suggestions and comments on further improvements of the site.
Venom Band Biography Topics
Related searchessybian specifications
enlightenment concept
pansy breeding and life cycle
dream interpretation tempted
roman legion symbols
h2s radar history
analytical psychology
About - Contact - Advertising
© 2000 - 2015 Realmagick.com, All Rights Reserved.
© 2000 - 2015 Realmagick.com, All Rights Reserved.


text:
Ilya Reznik, together with The Reznik Group, has taken Miami luxury real estate sales and marketing to an unprecedented level with the most comprehensive market reports and network of professionals, who provide exceptional personalized service. When it comes to Miami luxury condos, his expansive knowledge and expertise is to bring together real estate buyers with real estate sellers whose residential needs closely match. His unique global matching system pairs international clientele of Miami luxury real estate properties with multilingual associates, which has resulted in many sales and happy buyers and sellers. Ilya's website allows one to view active and sold Miami & Greater Miami Beach luxury condos and properties online and detailed property information for all listings. Conveniently browse Sunny Isles Beach luxury condos, Bal Harbour luxury condos, Aventura condos for sale and many more from your home or office. Over 150 luxury condominium developments from South Miami to Fort Lauderdale & Palm Beach and over 45 South Florida preconstruction and under construction luxury condominium properties are featured here on this site.
Ilya Reznik is able to substantially increase our clients' success, because of not just his network within the U.S. but also our international connection in many countries around the globe, including Russia to attract foreign cash buyers. Russian investors and buyers are still many of the largest purchasers of luxury real estate in the Greater Miami Beach area of South Florida. Russians have the purchasing power to take advantage of Miami's real estate market.
Specializing in the sale and purchase of Miami and Sunny Isles real estate, including Sunny Isles Beach condos and Miami & Miami Beach luxury condos for sale. Whether you are thinking about investing, buying a second home or selling your property, feel free to contact Ilya Reznik directly to receive the concierge-level of service and experience you deserve.
Mobile: +1.786.853.0191
E-mail: email@example.com
Copyright ©2015 - Realty Times®
All Rights Reserved.


text:
Fairmount Park in Camp Hill, PA
Luxury living at its best! Fairmount Park welcomes you to discover lavish living at our uniquely designed apartment community! Give us a call today!
Fairmount Park400 W Crestwood Drive, Camp Hill, PA 17011 USA
Floor Plans and Pricing
|$700 - $750
|1 Bathroom
|400 sq. ft.
1 Bedroom
|One Bedroom
|$760 - $920
|1 Bathroom
|860 sq. ft.
2 Bedrooms
|Two Bedroom
|$860 - $1,030
|1 Bathroom
|1,000 sq. ft.
3 Bedrooms
|Three Bedroom
|$1,140 - $1,300
|2 Bathrooms
|1,200 - 1,225 sq. ft.
- |
- |
- |
- Application Fee:
- |
- Deposit:
Property Features
- Property Overview
- Special Features
- Community Features
- Apartment Amenities
- Local Schools
- Pet Policy
Fairmount Park in Camp Hill, PA
Settled in the serene views of Camp Hill, Pennsylvania, Fairmount Park offers spacious studio, one, two, and three apartment homes for rent. Each of our newly renovated apartment homes features beautifully designed gourmet kitchens, spacious garden baths, and oversized closets. Enjoy our great community amenities such as our spacious sport courts, grilling areas, and resort-style swimming pool. Fairmount Park is conveniently located in the heart of Camp Hill and offers easy traveling access to major highways and shopping centers, fine dining choices, and live entertainment attractions. Reserve your newly updated apartment home at Fairmount Park today!
Special Features
- Sparkling Swimming Pool
- Sports Court
- Near Public Transportation
- High Speed Internet Access
- BBQ/ Picnic Area
- Playground
- Basketball Courts
- Newly Renovated Apartments
- Built In Microwaves
- Large Closets
- Gourmet Kitchens
- Washer/Dryer In Upgraded Apts
Community Features
- Accepts Credit Card Payments
- Apartment
- Courtyard
- Freeway Access
- On Street Parking
- Playground
- Pool
- Public Transportation
- Standard
- Street
- Surface Lot
- View
Apartment Amenities
- Air Conditioning
- Cable or Satellite
- Carpet
- Ceiling Fan
- Dishwasher
- Extra Storage
- Hardwood Floor
- Microwave
- Patio or Balcony
- Walk In Closets
- Washer Dryer In Unit
Local Schools
- Cedar Cliff High School
- New Cumberland Middle School
- Washington Heights Elementary School
We believe school data to be accurate, but do not guarantee that. Please be sure to verify where your children will attend school before making your housing decision.
Pet Policy
Pets are welcome. Please call for pet details.
- Pets Allowed
Contact Fairmount Park
Fairmount Park
Office HoursMonday - Friday 8:30am - 4:30pm Saturday: 10:00am - 2:00pm Sunday: Closed
Nearby Suggested Apartments
- No suggested apartments at this time. Try again later.
As you search for your perfect apartment, please keep in mind that rental rates (including specials and discounts) and availability are very fluid in the apartment industry. Based on many factors, the rental rates (including specials and discounts) and availability can actually change not just daily, but hourly, if not even more quickly. While our advertisers do take steps to keep their information current, the rental rates or availability you may find here now at ForRent.com may not be the same as when you contact the communities.


text:
AEterna Zentaris Inc. Stock Quote & Summary Data
Industry: Health Care
Community Rating:
Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Symbol Lookup
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now
Company Description (as filed with the SEC)
We are a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. We were incorporated on September 12, 1990 under the Canada Business Corporations Act (the "CBCA") and continue to be governed by the CBCA. Our registered address and head office is located at 1405 du Parc-Technologique Blvd., Quebec City, Quebec, Canada G1P 4P5; our telephone number is (418) 652-8525 and our website is www.aezsinc.com. None of the documents or information found on our website shall be deemed to be included in or incorporated by reference into this Annual Report on Form 20-F, unless such document is specifically incorporated herein by reference. On December 30, 2002, we acquired Zentaris AG, a biopharmaceutical company based in Frankfurt, Germany. Zentaris was a spin-off of Asta Medica GmbH, a former pharmaceutical company affiliated with Degussa AG. In May 2004, we changed our name to Aeterna Zentaris Inc. ... More ...
Risk Grade
Where does AEZS fit in the risk graph?
Additional Info
Analyst Info
|Annual EPS Est:
|Quarterly EPS Est:
|PEG Ratio:
|Mean Recommendation:


text:
The Brew Competition Online Entry & Management (BCOE&M) system is an online application to assist homebrew competition hosts (of the beer variety) to collect, store, and output participant and entry data.
One of the biggest challenges of organizing a homebrewing competition is knowing who has entered what and how many come competition day. BCOE&M provides an online interface to collect this information beforehand and output it to compliant software for use on competition day.
Homebrew competition organizers that wish to have an online entry portal that can gather all of the necessary data from participants and their asscoiated entries.
The application is available for free from GitHub and SourceForge, ready for installation on your website's server.
BCOE&M is an open source program covered under the General Public License (GPL) from the Open Source Initiative.
The full source code is available for free.
Click the "Download Zip" or "Clone in Desktop" buttons.


text:
PHOENIX — The Rockies finally took care of business Saturday night.
No one was more buttoned down than starter Jason Hammel. The right-hander sandwiched six excellent innings around one bad one, setting up the Rockies' 10-4 victory over the Diamondbacks at Chase Field.
And the Rockies dusted the cobwebs off their dormant offense with a five-run ninth, the key hits a run-scoring double by Ryan Spilborghs, an RBI-infield single by Yorvit Torrealba and a three-run, pinch-hit missile to right by Jason Giambi.
The victory tightened the Rockies' grip on the National League wild-card lead. With 13 games remaining, they lead the Giants by 3-1/2 games, the Marlins by four and the Braves by 4-1/2.
Hammel improved to 9-8, steadying the Rockies' shaky ship with a four-hit, five-strikeout performance.
Giambi is 4-for-10 with nine RBIs and seven walks since joining the Rockies. His home run off Scott Schoeneweis was his first in purple pinstripes.
The evening couldn't have started off any better for the Rockies. The Dodgers had already crushed the Giants 12-1 earlier in the day, boosting the Rockies' wild-card lead.
Carlos Gonzalez strolled to the plate and led off the game with a 390-foot homer off hard-throwing Max Scherzer. Two batters later, Troy Tulowitzki connected on his fourth homer in his last four games, this one a solo shot to center. Tulowitzki's 29th homer put the Rockies in front 2-0.
Prosperity didn't last long. Arizona pulled ahead 3-2 lead in the third on Justin Upton's three-run homer off Hammel. Upton's 25th homer was a no-doubt, 424-foot blast to center. Arizona set the table for Upton with singles by Scherzer and Chris Young. At that point Hammel looked ready to cave in, but he didn't. Instead, he held the Diamondbacks hitless over the next four innings.
That gave the Rockies plenty of time to rally. They scratched out two runs in the fourth, taking a 4-3 lead thanks to an assist from Diamondbacks left fielder Gerardo Parra. With the bases loaded, Ian Stewart hit a towering sacrifice fly down the left-field line. Parra had no real shot to throw out Tulowitzki, tagging up from third, but he airmailed a throw anyway. The ball bounced beyond home and into the stands, allowing Brad Hawpe to score from third.
In the seventh, a leadoff double by Gonzalez, followed by an RBI pinch-hit double by Spilborghs extended the lead to 5-3.
The Diamondbacks staged a brief rally in the eighth. Facing Rockies setup man Rafael Betancourt, Stephen Drew tripled to center to lead off, scoring on Upton's sacrifice fly. But Betancourt rallied, closing out the inning striking out Mark Reynolds on a 3-2 pitch.
Patrick Saunders: 303-954-1428 or email@example.com


text:
Empyre Skeletor Camo Stretch Cargo Pants
Item # 204496
Take an Additional 30% Off
Stash Points: 998
What is this?This is the number of points you get in The Zumiez Stash for purchasing this item. Stash points are redeemable for exclusive rewards only available to Zumiez Stash members. To redeem your points check out the rewards catalog on thestash.zumiez.com.
Army crawl through the trenches, fight off invading hordes, or tear up the skate parks in the Empyre Skeletor skinny camo stretch cargo pants that even John Rambo would approve of.
|More Details
Waist/Inseam Sizing:


text:
This Norwegian Valley Town Built an Artificial Sun To Brighten the Darkness
Rjukan is a small Norwegian town of roughly 3,300 residents nestled in a valley in northern Norway. Because of its unique geographic location, the town is cloaked in darkness for five months every year.
But not for much longer! A new project is installing mirrors on a mountaintop that overlooks the city and will shine a artificial sunlight into the town. Exposure to sunlight helps ward off depression and sadness, so the town of Rjukan just might be a little more cheerful this winter.


text:
If I wanted to make it larger can't I just continue doing rounds? Or do I need to do something special.
Pattern for lap blanket
Posted 11/14/2012
Comments (1)
Posted 11/15/2012
I think it depends on the pattern itself... do you have a picture or the pattern/diagram you can post of the lap sized quilt?
DH, DD March 2009, DS June 2011, DD March 2014, 3 first trimester losses
My 24hr Breastaurant is back in business!


text:
Como : Class Text Introductory Spanish Proficiency
AUTHOR: Juan Manuel Gomez, William B. Fischer, Earl L. Rees, Peter N. Richardson
EDITION: 2nd
PUBLISHER: Pearson Learning Solutions
Also available at Amazon.com
This book is not guaranteed to come with supple-
mental materials (access codes, CD's, DVDs, etc.)
mental materials (access codes, CD's, DVDs, etc.)
21 Day Unconditional Guarantee
any book, any reason


text:
Miss Kitty By Aristocrat
Developer: Aristocrat Technologies Inc.
✿ Release Date: Aug 31, 2011
✿ Version: 1.0
✿ Size: 22.47 MB
Need help? Use our Miss Kitty By Aristocrat Walkthrough or sign up and make your contribution today.
This iOS application is compatible with iPhone 3GS/4, iPad 1/2, iPod Touch 3rd.
Aristocrat Technologies Inc has already given us 5 Dragons by Aristocrat on Nov 27, now delivering another great Casino game and iphone app on the store. The review includes the developer's description, customer ratings, user reviews and screenshots for iPhone, iPad, and iPod touch.
if you like this mobile application, please share It with others (click on the social media icon links).
• Sticky Wild Free Games Feature: when 3 scattered MOON symbols appear, 10 free games are won. Any CAT appearing during the free games stays in the window at
that position for the remainder of the free games, and substitutes for all symbols except scatters. Scattered MOON occurring beneath CAT may even contribute to a scatter prize. Just check and see if the symbols alternate on the screen.
The Sticky Wild Free Games feature can be triggered again during the feature once only, with 5 free games awarded.
Now, we're gonna let the cat out of the bag: remember this is a play-for-fun app, not play-for-money. This game does not replicate the odds of winning or the payouts of similar Aristocrat games.
Like what you see here? Then try some of our other great iOS apps or get your paws on Aristocrat slot machines at your nearest casino.
Remember, you must be 21 to gamble.
For more information on responsible gambling, visit americangaming.org.
Get now this application with your unique ID and secured password.
This application support GameCenter feature for achievements and leaderboards.
Application Screenshots
How to download the GameDownload Miss Kitty By Aristocrat app for for iPhone, iPod Touch, iPad and iPad mini.
Download Miss Kitty By Aristocrat on PC or Mac:
1. Go to the Miss Kitty By Aristocrat application page in your iTunes.
2. Click the button to download the Game.
3. Sync your iPhone, iPod Touch, iPad or iPad mini with iTunes to install the Miss Kitty By Aristocrat app.
Download the Game With iOS App Store:
1. Open the App Store on your iDevice.
2. Search for Miss Kitty By Aristocrat.
3. Click the button to download and install it on your device.
4. Enjoy.
You can securely create an apple profile with your information, but you have to be registered to iTunes in order to get the Miss Kitty By Aristocrat app to your device.
If you don't have an active account, please register to iTunes store with a credit card number. In case you are not interested to open an account with your credit card, you can select the option 'None' during the secured registration.
*This Miss Kitty By Aristocrat application may be available in some countries.
Video Play Review
How to play
here you will find every thing you need to help you pass and complete all levels, includes guides / walkthrough, hints, tips & cheats, you will find here the best solutions and answers for all levels in this Casino.
User Ratings
Love Miss Kitty and 5 Dragons but please bring Tigress! My all time favorite at casino.
This app needs to be updated along with other titles, such as sun and moon, and geisha. Miss kitty, sun and moon and geisha all
worked on the iPhone 6 but for some reason won't load on the iPhone 6 pl
Have you quit putting out new slots?
The dream setting is very far from dreamlike. For a paid app, they have nothing to lose making the dream setting very loose. Coins
are unlimited, there are no in app purchases but this game plays like
we need new aristocrat apps like more chilli and more hearts as its getting quite old these games have got all the apps aristocrat
needs to release new ones soon its been a long time sice a new releas
Love to play slots machine need more games
Like your games. Please, Wings Over Olympus.
Please release big red - its your best game!
Mine quit spittting out the coins when I hit a large amount. 50/100 Lions and or Star Drifter would be magnificent!
Great game! Would love to see my all time favorite "Queen of Atlantis" next! Your slots are the only ones I play in the casino:)
Love these slots! But add Pelican Pete next!
What a game of fun
I love all of the games. I wish I could play SticknRich and Outback Jack on my iPhone.
The following games need to be fixed so that when using an ipad we do not have to use the 2x button so that they can be like the
newer slots
Love it!
Please release "where's the gold"
Almost like the live game...even the losses! I am hoping amazing money machine is coming! Great game
I love this game, the bonuses are great sometimes & sometimes they're not
just like at the casino. Y
Wow, playing dream mode and can't win or get a decent paying bonus. Would be more fun if I could wi
it,s a very fun game but when will you guys realease time machine, tikki torch, wheres the gold
(3★) Fun but needs bonus issue fixe
Fun slot game but way to hard to get bonuses!! It takes too long and too much money to ever get a bo
(3★) Fun but needs bonus issue fixed
Fun slot game but way to hard to get bonuses! It takes too long and too much money to ever get a bon
When are you going to release more games?????
Awesome! I play it even more at the casino now that I own it. So many more games I love - Pelican Pe
Love, love it!! Just like the casino but, I don't lose all my money~ thank you ARistocrat!
Please get "Where's the Gold!"
...like so many other Aristocrat game reviews I've read, when will we see BUFFALO? Like so many oth
It's like having my own casino anywhere! Atistocrat slot games are by far the best i ever compared t
Love love love all ...wicked winnings doesn't pay out so well nut then again it doesn't pay in the c
Love these slots. Can you please consider releasing Panda ( where you spell panda for the bonus) and
(5★) Love these games
These are my favorite please add wicked winnings III and more hearts and keep adding more I will bu
This is one of the games I always play when im at the casino... Totally awesome that this came out..
Love the games. How bout some Love and War
Keep up the good work, and for chrissakes, please, I beg of you, RELEASE 50 LIONS ON iOS!
GOLDFISH! oh wait....I don't know if aristocrat is responsible in making that game. But miss kitty i
PLEASE....PLEASE...PLEASE....Release Pompeii 2 as a purchasable app...You guys rule the slot apps by
(5★) H.H.S.M.(Hand Held Slot Machin
Thank you, you are on the right track! Keep them coming. The best promo for the real machines. 50 Li
I have all your slot games, and I have to say this one probably has the best paying odds. The only
Total 38 reviews with ratings for this app.


text:
How to Dispose of Fireworks
Spent fireworks and duds remain hot after use, and have the potential to spark fires. Don't end your party prematurely due to a careless disposal of your fireworks.
This article has been tagged as a stub.
That means it's off to a good start, but still has room to grow into a more helpful resource. Until the article reaches its full potential, it will be hidden from search results. Can you help it flourish? If you think the article offers complete and accurate instructions, feel free to remove this tag.
1Before lighting fireworks, fill a couple of buckets with water and keep them close at hand.
2After use, scour the area for loose debris. Fireworks left on the ground are capable of starting fires.
3Spent fireworks, dud fireworks and sparklers should be immersed in water immediately after use.
4Alternatively, spray spent and dud fireworks from a distance using a garden hose for extra safety.
5Wrap the soaked fireworks in trash bags and place in the trash.
6If you are unsure, your local fire department will likely accept fireworks and ensure proper disposal.
7live fireworks are disposed in the same manner, however, the fuse should be removed first to prevent detonation.
Give us 3 minutes of knowledge!
- Wear gloves to protect your hands.
- Point fireworks away from you and others in case they discharge.
- Use fireworks sensibly.


text:
|Boxing Champions | Boxing Schedule | Boxing Video | Boxing History | Pound For Pound | The Wire | Ratings | Arcade
|Home Tags index Lucian Bute
|Roy Jones: Pascal Should Avoid Trying To Box Bute
Former four division world champion Roy Jones Jr. is spending some time at Big Bear and helping Jean Pascal (28-2-1, 17KOs) with his strategy for the upcoming fight Lucian Bute, on January 18th at ...
reviews | forums
|Pascal: I'm Still The Cash Cow at Light Heavyweight
Despite his inactivity over the last two years, and the rise of such champions like Sergey Kovalev and Adonis Stevenson, former WBC champion Jean Pascal (28-2-1, 17KOs) is confident that he's still...
reviews | forums
|Lucian Bute: Pascal Fight Could Become One-Sided
Lucian Bute (31-1, 24KOs) feels very confident as his training camp continues for the all-Canadian battle with fellow former champion Jean Pascal (28-2-1, 17KOs). Bute moves up to the light heavywe...
reviews | forums
|Photos: Lucian Bute Putting in Work For Jean Pascal
Former super middleweight chmapion Lucian Bute (31-1, 24KOs) is training hard for his Canadian super-fight with Jean Pascal (28-2-1, 17KOs), a former light heavyweight champion. The long awaited ma...
reviews | forums
|Pascal-Bute Not Necessarily Facing Stevenson Next
Canadian stars Lucian Bute (31-1, 24KOs) and Jean Pascal (28-2-1, 17KOs) are getting ready for their super-fight on January 18th at the Bell Centre in Montreal. The World Boxing Council has approve...
reviews | forums
|Mike Perez-Carlos Takam on Pascal-Bute Undercard
Montreal � InterBox and Groupe Yvon Michel (GYM) and proud to announce the undercard bouts for the historic January 18th 2014 Bell Centre clash between former World champions Lucian Bute (31-1-0, 2...
reviews | forums
|Thomas Oosthuiezen-Eleider Alvarez on Pascal-Bute
Fresh from a less than stellar performance when he saw off Ezquiel Maderna's challenge to his IBO super middleweight title, talented Thomas �Tommy Gun�Oosthuizen will move up to the light heavyweig...
reviews | forums
|Pascal vs. Bute Sanctioned By WBC For Diamond Title
The World Boxing Council has sanctioned the WBC light heavyweight Diamond belt for the Canadian super-fight between Jean Pascal (28-2-1, 17KOs) and Lucian Bute (31-1, 24KOs), scheduled to take plac...
reviews | forums
|Photos: Bute, Pascal Go Face To Face in Montreal
The official press conference took place to announce the rescheduled date for the Canadian super-fight between former champion Jean Pascal (28-2-1, 17KOs) and Lucian Bute (31-1, 24KOs), which takes...
reviews | forums
|GYM: Stevenson Will Not Fight on Bute-Pascal Card
The worst question you can ask a fighter prior to a fight is who he would next like to face; the answer is almost always, �I�m focused on the opponent in front of me.� Adonis Stevenson isn�t aff...
reviews | forums
|Adonis Stevenson Says Bute vs. Pascal is a 50-50 Fight
Newly crowned WBC light heavyweight king Adonis Stevenson credits his current trainer Javan Hill and his former trainer, the late Emmanuel Stewart, for helping him become a world champion. Stevens...
reviews | forums
|Dawson Eyes Bute-Pascal Winner, Hopkins Trilogy
Chad Dawson is looking to get back in the win column and show that he�s still the best Light Heavyweight in the world as he takes on hard hitting Adonis Stevenson this Saturday night live on HBO. D...
reviews | forums
|Carl Froch on Lucian Bute: Mentally He's a Broken Man
Carl Froch wanted a second shot at Mikkel Kessler the second Kessler was announced as the winner of their April 2010 super middleweight title fight in Herning, Denmark. Froch understands, howeve...
reviews | forums
|Bute-Pascal: January 25 Also Set Aside For New Date
Montreal - InterBox and Groupe Yvon Michel (GYM) have reserved the dates of Saturday, December 7th and Saturday, January 25th at the Montreal Bell Centre for the postponed Bute vs. Pascal bout. ...
reviews | forums
|Bute-Pascal Showdown Rescheduled To December 7th
The Canadian super-fight between Lucian Bute and Jean Pascal has been rescheduled for December 7th at the Bell Centre in Montreal, according to InterBox. Bute (31-1, 24 KOs) vs. Pascal (27-2-1, 16 ...
reviews | forums
|Bute-Pascal Undercard Bouts Moved To Dawson-Stevenson
Montreal � After internal discussions, InterBox and Groupe Yvon Michel (GYM) have jointly decided against promoting a boxing event on Saturday, May 25th at the Montreal Bell Centre. Preferring to ...
reviews | forums
|Bute's Faces Tough Recovery, Eyes Return By Year's End
Lucian Bute�s trainer stated Tuesday that the hand injury that forced Bute to withdraw from his May 25 fight against Jean Pascal was a lingering nuisance that worsened during a sparring mishap last...
reviews | forums
|Bute Injures Left Hand, Withdraws From Pascal Bout
Yvon Michel, promoter for former light heavyweight champion Jean Pascal, advised BoxingScene.com that Lucian Bute has injured his left hand and as a result he withdrew from the scheduled fight agai...
reviews | forums
|Video: Jean Pascal Interview and Training For Bute
Ryan Burton catches up with former light heavyweight champion Jean Pascal as he prepares for his battle with domestic rival Lucian Bute.
reviews | forums
|Photos: Gamboa, Pascal, Dawson Las Vegas Media Day
On Thursday afternoon, former light heavyweight champion Jean Pascal (27-2-1, 16 KO�s) could be found inside of 50 Cent�s newly-built boxing gym in Las Vegas, as he hosted the media ahead of his Ma...
reviews | forums
Cookie Policy - Privacy Policy - Submit News - Feedback - Site Map - Advertise with Us
Copyright � 2003-2015 BoxingScene LLC. All rights reserved.


text:
Austrian Poland Church RecordsEdit This Page
From FamilySearch Wiki
Birth Records
The early birth records show:
The year and date of birth and baptism
The House number
Given name / religion/ sex of the child/ if it was a legitimate child
Father's name
Mother's name and her father
The later records show additionally:
On the top we have the page number
We have the entry number
The child's name with death inform
Father's occupation and parents
Mother's parents
When you request the extract from the Civil Registrar Office in the Ukraine, the following is what you can expect from the information on the original document:
Information shown on the extract:
Name of the child
Date and place of birth
Entry number and day of entry made
Father's fist, last name and his father's first name
Mother's first, maiden name, and her father's first name
Marriage Records
Name of the parish
Page number
Date of the marriage
House numbers for groom and bride
Groom's first, last name, names of his parents, his marital status, age
Bride's first, maiden name, names of her parents, marital status, age
Death Records
Page number
Date of death and entry
House number
Name of deceased and her spouse
Place of death
Cause of death
Status Animarum - List of Parishioners
Information included:
Entry number
First and ancestral name of the couple
Date of marriage
Date of birth for the husband and wife
House number (here not given)
The children's first names
The children's dates of birth
The grandparents on both sides and their dates of birth
Need wiki, indexing, or website help? Contact our product teams.
Did you find this article helpful?
You're invited to explain your rating on the discussion page (you must be signed in).
BROWSEby country by topic
Future Changes to the Wiki
Changes are coming to the FamilySearch Research Wiki in the near future. Find out more on the Wiki Community News page.Community News


text:
HENDERSON, KY (4/18/12) – Detectives with the Henderson Police Department have been investigating a string of burglaries and thefts that took place in the area of Janalee Drive recently.
Yesterday, April 17, 2012, Henderson police officials located items that were linked two to of the thefts in the area, tracked to 35-year-old Julie Podlinski of Janalee Drive.
Podlinski was arrested and charged with one count of Burglary (2nd Degree) and two counts of Theft of a Controlled Subtance.
Podlinski is currently lodged at the Henderson County Detention Center.
SurfKY News
Information provided by the Henderson Police Department
LIKE SurfKY on Facebook - Click here to LIKE us now.
© Copyright 2015 SurfKY News Group, Inc. All rights reserved. This material may not be published, broadcast, or rewritten without permission. SurfKY News encourages you to share this story on social media.
|< Prev
|Next >


text:
Genesis 1-11: New Daily Study Bible [NDSB]
- All Products
- Academic
- Accompaniment Tracks
- Audiobooks
- Bible Accessories
- Bible Covers
- Bible Studies & Curriculum
- Bibles
- Black Friday Deals
- Books
- Buy in Bulk
- Catholic
- Children
- Christian Living
- Christmas
- Church & Pastoral
- Church Supplies
- Closeouts
- Clothing & Accessories
- Crafts & Recreation
- Cyber Monday
- Download
- DVDs
- eBooks
- eBooks On Sale
- Family
- Fiction
- Gift & Home
- Homeschool
- Last Chance Bargains
- MP3 Music Downloads
- Music
- New Release
- Non-Fiction
- Pre-Order
- Slightly Imperfect
- Software
- Spanish
- Subscriptions
- Sunday School
- Teens
- Videos
Product Description
Product Information
|Format: Paperback
Vendor: Westminster John Knox Press
Publication Date: 1981
Dimensions: 5 X 7 1/4 (inches)
Availability: In Stock
Series: Daily Study Bible
Other Customers Also Purchased
The Gospel of Luke: Sacra Pagina [SP]Luke Timothy JohnsonMichael Glazier / 1991 / Hardcover$34.99 Retail:
$49.95Save 30% ($14.96)Availability: In StockCBD Stock No: WW58059
An Introduction to the New Testament: Witnesses to God's New WorkCharles B. CousarWestminster John Knox Press / Trade Paperback$4.99 Retail:
$30.00Save 83% ($25.01)Availability: In StockCBD Stock No: WW22413X
The Westminster Handbook to Women in American Religious HistorySusan Hill Lindley, Eleanor J. StebnerWestminster John Knox Press / 2008 / Trade Paperback$4.99 Retail:
$30.00Save 83% ($25.01)Availability: In StockCBD Stock No: WW224547
Theology Today: Reflections on the Bible and Contemporary LifePatrick D. MillerWestminster John Knox Press / 2006 / Trade Paperback$2.99 Retail:
$17.00Save 82% ($14.01)Availability: In StockCBD Stock No: WW229921
Related Products
The New Daily Study Bible, 17 Volumes: New TestamentWilliam BarclayWestminster John Knox Press / Trade Paperback$152.99 Retail:5 Stars Out Of 5 20 Reviews
$230.00Save 33% ($77.01)Availability: In StockCBD Stock No: WW22802X
The Old Testament, 24 Volumes: Daily Study Bible [DSB]John C.L. Gibson, ed.Westminster John Knox Press / 1987 / Trade Paperback$279.99 Retail:
$350.00Save 20% ($70.01)Availability: In StockCBD Stock No: WW24069
Jeremiah, Volume 2 & Lamentations: New Daily Study Bible [NDSB]Robert DavidsonWestminster John Knox Press / 1986 / Trade Paperback$11.99 Retail:5 Stars Out Of 5 1 Reviews
$18.00Save 33% ($6.01)Availability: In StockCBD Stock No: WW24581
Ecclesiastes & Song of Solomon: New Daily Study Bible [NDSB]Robert DavidsonWestminster John Knox Press / 1986 / Trade Paperback$16.20 Retail:
$18.00Save 10% ($1.80)Availability: Usually ships in 24-48 hours.CBD Stock No: WW4245897
Publisher's Description
In this first of two volumes on the book of Genesis, John Gibson--Old Testament General Editor of the Daily Study Bible--offers a probing investigation of the first eleven chapters of Genesis. He provides a perceptive verse-by-verse and even word-by-word examination of the well-known Genesis stories of creation, the garden of Eden, Cain and Abel, Noah and the flood, and the Tower of Babel.
Carrying forward brilliantly the pattern established by Barclay's New Testament series, the Daily Study Bible has been extended to cover the entire Old Testament as well. Invaluable for individual devotional study, for group discussion, and for classroom use, the Daily Study Bible provides a useful, reliable, and eminently readable way to discover what the Scriptures were saying then and what God is saying today.
Author Bio
Product Reviews
Ask Christianbook
Ask Christianbook
Find Related Products
- Academic >> Commentaries >> Old Testament >> Genesis
- Books >> Commentaries >> Old Testament >> Genesis
- Start A New Search


text:
- 38Promote
Art Print
Loneliness....by Wood-n-Images
Collect your choice of gallery quality Giclée, or fine art prints custom trimmed by hand in a variety of sizes with a white border for framing.
"It's hard being left behind. It's hard to be the one who stays" I feel this way after the loss of my lovely wife of 40 years
I am so sorry. I know my great uncle feels the same way. He is probably in his 70's, lost his wife, one of his best friends(my grandpa), and wives sister(my grandma). He is saying the same thing. I do not blame you at all but there are people here that still would like to have you around till it is your time. I bless you right now and wish you the absolute best!
Thanks so very much Ben, and yes I feel very lonely, but I want to hang around to at least see my Grandsons' grow up which is a long way off. I am not going anywhere until the good lord call me.
I am very glad! I know he got a good 8 grandchildren(lol their side of the family multiplies like bunnies) since and seems to be happy to be around for them.
We love you Richard, it will be a bit easier in time, my best prayers so you feel a shiny sun inside you and lots love to warm you up. Ben said it lovely. I'm so happy to have you here :) ♥
Great shadow & light! ♥
Time heals.... I do know that.
Time heals.... I do know that.
So cool! Wonderful light and shadow!
Take care!! ♥
fantastic shot and great eye!
Thanks everyone for your support .
it speaks from the heart haunting
Beautiful b&w work
See More Comments


text:
Forget password?
Remember Me
Banga was recorded at Electric Lady Studios in New York City and produced by Patti Smith and her band: Tony Shanahan, Jay Dee Daugherty and her long-time collaborator Lenny Kaye. Featured guests include Tom Verlaine, Jack Petruzzelli, Smith's son Jackson and daughter Jesse Paris.
Inspired by Smith's unique dreams and observations, Banga's poetic lyrics are a reflection of our complex world - a world that is rife with chaos and beauty. Praised for her storytelling abilities, Smith has crafted an album that captures a wide range of human experience.
There is an exploratory spirit in the songs that make up Banga, including a melodic overture imagining the voyage of Amerigo Vespucci to the New World in 1497 (Amerigo), a rock song for the people of Japan in the wake of last years earthquake (Fuji-san), a classic ballad in memory of Amy Winehouse (This Is The Girl), an improvised meditation on art and nature (Constantine's Dream) as well as a birthday song written for her friend Johnny Depp (Nine).
Banga Tracklisting
Patti Smith Tour Dates
Patti Smith News


text:
Skip Ribbon Commands
Skip to main content
Cottage Grove Community Medical Center Foundation
Ketchikan Medical Center Foundation
Peace Harbor Medical Center Foundation
Sacred Heart Medical Center Foundation
Southwest Medical Center Foundation
St. John Medical Center Foundation
St. Joseph Medical Center Foundation
All PeaceHealth Foundations
Medical Professionals
Community Benefit Reports
Community Health Needs Assessment
Community Magazines
Community Sponsorship Application
For PeaceHealth Caregivers
For the Media
For Vendors
Patient Financial Services
PeaceHealth Mission, Values & History
show menu
PeaceHealth St. Joseph Medical Center
Women's & Children's Services Home
Childbirth Center Home
Birthing Services & Postpartum Care
Pre-Admission Registration
Before You Arrive
What to Bring
Where Will I Deliver?
Labor & Delivery
Comfort & Pain
Premature Babies
Your Stay
Legal Documents & DSHS Benefits
Breastfeeding Support
Going Home
Security & Visitor Guidelines
Care Team
Find a Provider
Certified Nurse Midwives
OB Hospitalist & Emergency Service
Additional Information
Family Health Resources
Safe Place for Newborns
Newborn Photos
Contact Us/Directions
Page Content
Breastfeeding Support
We promote breastfeeding and understand that this can be a difficult task at first. Our lactation consultants are available seven days a week for one-on-one intensive support. They're experts in educating and counseling moms through their breastfeeding journey. In addition, all nursing staff are trained in breastfeeding issues.
Breastfeeding is a skill that takes time to learn. If you have returned home and are having feeding issues, it's important to
contact us for assistance
You can rent breast pumps for home use. Please ask your nurse for more information.
Breastfeeding Resources
Breastfeeding overview
Should I breastfeed my baby?
Breastfeeding: Learning how to nurse


text:
Children's Hospital is part of the UPMC family.
Our Sites
Explore our health libraries designed for kids and teens.
To find a pediatrician or pediatric specialist, please call 412-692-7337 or search our directory.
A resource for our network of referring physicians.
For more information about research, please call our main office at 412-692-6438.
Children's Hospital is ranked One of America's Best Children's Hospitals.
Welcome to the Brain Care Institute at Children's Hospital of Pittsburgh of UPMC. Our unique collaboration between top experts in pediatric neurosurgery and neurology allows us to offer complete care for children with brain, spine, and nerve problems.
Listen to the doctors and health care team at Children's who are making breakthroughs in pediatric neurosciences.
From the paint colors to the pediatric ICU, we designed Children's Hospital of Pittsburgh for kids — and only kids.
Watch how one family found help — and hope — through the expert care at the Brain Care Institute.
Clinical Studies
Children's Hospital of Pittsburgh of UPMC4401 Penn AvenueFloor 2Pittsburgh PA , 15224412-692-5520
Children's Hospital of Pittsburgh of UPMC4401 Penn AvenueSuite Floor 2Pittsburgh PA, 15224412-692-5090
11279 Perry HighwayWexford PA, 15090412-692-7337
205 Millers Run RoadBridgeville PA, 15017412-692-7337
4055 Monroeville Blvd.Building OneMonroeville PA, 15146412-692-7337
2580 Constitution Blvd.Beaver Falls PA, 15010724-773-6851
118 East 2nd StreetW1150Erie PA, 16057814-877-8701
875 North Hermitage Rd.Hermitage PA, 16148724-347-4596
865 Eisenhower Blvd.Johnstown PA, 15904814-266-8840
10 Medical ParkTower 1, Suite 305Wheeling WV, 26003304-243-3276
Children's Hospital of Pittsburgh of UPMC4401 Penn AvenueFloor 2Pittsburgh PA, 15224412-692-5520
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children's Hospital of Pittsburgh of UPMC
One Children's Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With MyCHP, you can request appointments, review test results, and more.
For questions about a hospital bill:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to:


text:
Thursby to ship ADmitMac v3 in mid-August
updated 12:05 am EDT, Thu July 21, 2005
ADmitMac v3 due next month
today announced that ADmitMac v3 is now in beta and is expected to ship in mid-August. ADmitMac offers secure and complete integration of Macs into Microsoft Active Directory environments. ADmitMac v3, which was delayed by critical bugs in Mac OS 10.4 (since corrected in v10.4.2), offers full support for Microsoft NTFS file system, allowing for storage of Mac files with multiple forks in a single file; it also delivers support for secure protocols, including NTLMv2 and SMB signing for connecting to Windows Server 2003 without downgrading the server security. Version 3 also brings complete support for Microsoft's Distributed File System (not currently available with Tiger) and includes both Mac/PC utilities for managing desktop settings. ADmitMac v3 also includes deployment tools for support of large and complex site installation. Pricing starts at $120 with free upgrades for purchases after April 1, 2005.


text:
Hi All,
Could someone who reads French tell me if this page sells Kodak chemistry to a private person? Kodak has branches in most EU countries and the pages all look similar. The reason I ask about France is that there still isn't an identified resource for chemistry there. This doesn't look like it offers raw chemicals, but I'd hate to see processing chemistry (most importantly, Photoflo 200) hold up the works. Thank you.


text:
A short custom story for Amnesia, designed by my house (I live in a flat). You wake up, you don't know where you are, you don't know how did you get there... You have to get away, or die.
Jul 9th, 2013 0 people agree 0 people don't
I liked the idea of the stairs and being able to explore a few of the rooms. It would have been really good had it been longer and had more exploration.


text:
Alogliptin is a new dipeptidyl peptidase (DPP-4) inhibitor, which is under investigation for treatment of type 2 diabetes either alone or in combination with other antidiabetic drugs. The aim of this meta-analysis was to assess the efficacy and tolerability of alogliptin in patients with type 2 diabetes.
Computer based search was performed in MEDLINE, Cochrane library, and HINARI (Health InterNetwork Access to Research Initiative) databases. Meta-analysis was carried out by incorporating double-blind randomized controlled studies done on the efficacy of alogliptin in patients with type 2 diabetes. The efficacy and tolerability of alogliptin was determined by standardized mean differences (SMDs) and Mantel-Haenszel odds ratio. Heterogeneity was assessed by the chi-squared test (Cochran Q test) and I2 statistics.
The pooled SMDs demonstrated a significant reduction in HbA1c in patients treated with alogliptin 12.5 mg (SMD = −0.81; 95% CI, -1.11 to −0.51) or alogliptin 25 mg (SMD= −0.98; 95%CI= −1.30 to −0.66) as compared with controls. The SMD for reduction in fasting plasma glucose level (FPG) from baseline was also statistically significant among alogliptin treated patients. However, the effect of alogliptin on body weight change was inconclusive. The proportion of patients who discontinued alogliptin due to adverse events was not different from controls. Similarly, the meta-analyses of specific adverse events did not demonstrate statistically significant differences.
Alogliptin alone or in combination with other antidiabetic drug has shown a significant reduction in HbA1c and FPG level in patients with type 2 diabetes. However, its consistent efficacy for longer duration of therapy needs further investigation.
Keywords:Alogliptin; Body weight; DPP-4 inhibitors; FPG; HbA1c; Meta-analysis; Type 2 diabetes
Type 2 diabetes is characterized by insulin resistance accompanied by progressive loss of pancreatic β-cells function [1,2]. Additionally, patients with type 2 diabetes secret smaller amount of glucagon-like peptide–1 (GLP-1) and have a decreased insulinotropic effect of glucose dependent insulinotropic polypeptide (GIP) [3]. The incretin hormones (GLP-1 and GIP) are produced in the small intestine in response to food intake, and then stimulate glucose dependent insulin secretion from pancreatic β-cells [4]. The stimulatory effect of GLP-1 is short lasting due to a rapid inactivation by the widely distributed DPP-4. The search for drugs that are able to mimic incretin hormones or prolong the half-life of incretins has led to the discovery of incretin hormone mimetics (exenatide and liraglutide) and DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin, linagliptin and alogliptin).
Among the DPP-4 inhibitors, alogliptin is still under investigation for treatment of type 2 diabetes as monotherapy or in combination with other antidiabetic drugs. Pharmacokinetic studies showed that alogliptin is absorbed rapidly in the small intestine, and primarily excreted via the renal system in unchanged form [5,6]. This drug has got approval for treatment of type 2 diabetes in Japan [7,8] and not yet approved by the Food and Drug Administration (FDA) of America in till this manuscript is written [9].
The prevailing approach to the treatment of type 2 diabetes is starting with single oral antidiabetic drug followed by dose escalation and then combination therapy [10]. However, there is a growing consensus on the earlier initiation of insulin therapy and the use of combination oral agents including incretin mimetics [10].
A recent systematic review and meta-analysis that assessed the long term safety of DPP-4 inhibitors relative to placebo has reported an insignificant adverse events and risk of infections [11]. However, the aim of this meta-analysis was to assess the efficacy and tolerability of alogliptin (25 mg and 12.5 mg), which is not yet approved in many countries as monotherapy and/or add-on therapy in patients with type 2 diabetes. The primary outcome indicators of alogliptin efficacy were change in percentage of HbA1c and FPG level from the baseline.
Search strategy
Computer based search for literature on alogliptin was performed by AB in MEDLINE, Cochrane library, and HINARI databases. Via HINARI, literature search were also conducted on publishers' websites (Elsevier Science-Science Direct, Nature Publishing Group, Oxford University Press, PsycARTICLES, Science, Wiley-Blackwell and Springer Link). The search was further strengthened by searching relevant literature from the reference lists of retrieved articles. The search terms include: alogliptin or NESINA® or SYR-322, type 2 diabetes mellitus, dipeptidyl peptidase-4 (DPP-4) inhibitors, hemoglobin A1C, FPG and body weight. During searching, the term alogliptin was used alone and in an alternate combination with other search terms with the help of Boolean logic (and/or).
Study selection
The inclusion criteria for this meta-analysis were: 1) double-blind randomized controlled studies that weighted the efficacy and tolerability of alogliptin against placebo or other antidiabetic drugs in patients with type 2 diabetes; 2) studies that were published in English and have a duration of therapy not less than 12 weeks; and 3) studies which recruited patients with baseline glycosylated hemoglobin level (HbA1c) ≥ 7% and studies that provide information on change in percentage of HbA1c for every treatment group (alogliptin 12.5 mg, alogliptin 25 mg and placebo or other drug). The study selection was independently conducted by both authors. When there were discrepancies, it was resolved by discussion and by reviewing the studies in detail.
Data extraction
After developing a common data extraction template, the following information were abstracted from the selected studies by both authors separately with standard Excel spreadsheet: name of authors, year of publication, study design, study location, drugs before and after recruitment, duration of therapy, sample size, least squared (LS) mean and standard deviation (SD) or standard error (SE) of changes (in hemoglobinA1c, FPG, body weight and serum lipids), number of patients achieving HbA1c ≤ 7%, number of patients with reduction of HbA1c by ≥ 1.0%, number of discontinued patients due to adverse event, and number of patients with a specific adverse events.
Operational definitions
In the selected studies, controls could receive placebo or other antidiabetic drug or other antidiabetic drug plus placebo. In this meta-analysis, the term alogliptin alone is to mean that patients were given either only alogliptin 25 mg or 12.5 mg. Similarly, alogliptin add-on is to mean that patients received either alogliptin 12.5 mg or 25 mg plus other antidiabetic drugs. Antidiabetic naïve is to mean patients who were not on antidiabetic drug; while antidiabetic drug experienced patients were on antidiabetic therapy before the start of the studies.
Data synthesis & statistical analysis
Before the actual meta-analysis was conducted, some mathematical transformations and unit conversions were done. In case of continuous variables (change in HbA1c, FPG, body weight and serum lipids), where SE was reported instead of SD, we changed it to SD by multiplying the SE by the square root of sample size (SD = SE*√N). In studies where the change in FPG was reported as mg/dl, it was converted to mmol/l by using an online converter [12]. In one study, we have extrapolated values for reduction of HbA1c by ≥ 1.0% from a bar graph [13].
The effectiveness and tolerability of the two doses of alogliptin (12.5 mg and 25 mg) alone and as an added-on with other antidiabetic drug as compared to placebo or other antidiabetic drug were determined using the random effects model. SMDs and Mantel-Haenszel (M-H) odds ratios were determined. SMD and 95% confidence intervals (95% CI) for the mean change in HbA1c, FPG, body weight and serum lipids from baseline were computed using the inverse variance method. The odds ratios and the 95% confidence intervals for achieving HbA1c ≤ 7%, reduction HbA1c by ≥ 1%, treatment discontinuations due to adverse events and experiencing adverse events (hypertension, hypoglycemia, skin or subcutaneous adverse events etc.) were computed with Mantel-Haenszel method.
To assess the heterogeneity among the studies, chi-squared test (Cochran Q test) and I2 statistics were used. An I2 value of ≥ 50% was considered as statistically significant. Subgroup analysis based on the use of alogliptin as monotherapy or add-on therapy (alogliptin alone vs alogliptin with other antidiabetic drug), patients' antidiabetic drug exposure history (antidiabetic drug experienced vs antidiabetic naïve) and the sites of the studies (studies in a single country at multiple sites vs multiple country studies) were planned and conducted. On the other hand, meta-regression was limited to one covariate (duration of therapy) to avoid false-positive findings. Sensitivity analysis was also conducted to see the stability of the pooled values and the change in I2 when any of the study was withdrawn from the analysis.
Risk of bias of individual studies was assessed with the Cochrane risk of bias tool. The predefined key domains include: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting and other bias. A bias that is unlikely to affect the result was considered as "low risk of bias", while a bias that raises doubt about the results was considered as "unclear risk of bias" and bias that seriously affect the results was considered as "high risk of bias". To evaluate publication/disclosure bias, we have used funnel plots. Nevertheless, the tests for funnel plot asymmetry were not done as recommended in meta-analyses of randomized controlled trials with fewer than ten studies [14]. We reported the meta-analysis by following the PRISMA checklist [15]. The analyses were conducted with Review Manager (RevMan) Version 5.1 software [16] and Comprehensive Meta-Analysis Software [17].
From the retrieved 82 publications on alogliptin, only ten published articles met the inclusion criteria (Figure 1). Seven of the studies were done in multiple-countries [13,18-23]; whereas three of the studies were done in a single country at multiple sites (all in Japan) [24-26] (Table 1). Six of the studies compared the effectiveness of alogliptin as add-on to other antidiabetic drug(s) against antidiabetic drug with placebo or without placebo [18-20,23,24,26] and the remaining four compared alogliptin alone with placebo [13,21,22,25]. The selected ten studies have included 4,339 patients with type 2 diabetes; 1,707 received alogliptin 25 mg alone or as add-on; 1,311 received alogliptin 12.5 mg alone or as add-on and the remaining 1,321 received placebo or other antidiabetic drug(s) with or without placebo. The risk of bias assessment in the selected studies demonstrated that there were no biases in randomization, blinding and selective reporting. However, other sources of bias cannot be ruled out.
Figure 1. Flow diagram to show studies selection process, 2012.
Table 1. Characteristic of studies included in this Meta-analysis, 2012
As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated with either dose of alogliptin (SMD = −0.81; 95% CI, -1.11 to −0.51; SMD= −0.98; 95% CI= −1.30 to −0.66 for alogliptin 12.5 mg vs controls and alogliptin 25 mg vs controls, respectively). However, heterogeneity test and sensitivity analysis showed the existence of a significant heterogeneity among the included studies and no improvement of heterogeneity with withdrawal of any of the study from the analysis, respectively. When any of the study withdrawn from the analysis, the pooled SMD swings between −0.87 and −0.68 for alogliptin 12.5 mg, and between −1.06 and −0.86 for alogliptin 25 mg.
Figure 2. Standardize mean difference of the change in HbA1c from subgroup analysis by study location, Alogliptin 12.5 mg vs Control, 2012.
Figure 3. Standardize mean difference of the change in HbA1c from subgroup analysis by study location, Alogliptin 25 mg vs Control, 2012.
From the pre-specified subgroup analyses, the use of both doses of alogliptin as add-on or alone (alogliptin alone vs alogliptin plus other antidiabetic drug) and patients difference in antidiabetic drug treatment experience (antidiabetic drug naive vs antidiabetic drug experienced) did not show a statistically significant variation. In other words, the treatment outcomes were not significantly different when alogliptin was used as monotherapy or as add-on therapy. Similarly, the treatment outcome was not dependent on patients' antidiabetic drug experience. However, the subgroup analysis showed a significant reduction in HbA1c in single country studies than studies in multiple countries.
Furthermore, the meta-regression on the influence of duration of alogliptin therapy (both 25 mg and 12.5 mg) on the reduction of HbA1c revealed that as duration of therapy gets longer, the effect on HbA1c reduction become minimal, which was a highly statistically significant (slope = 0.06, 95% CI = 0.033 to 0.09 and P-value < 0.0001 for alogliptin 12.5 mg; slope = 0.07, 95% CI = 0.05 to 0.095 and P-value < 0.0001 for alogliptin 25 mg).
In comparison to controls, the proportion of patients achieving HbA1c ≤ 7% was significantly higher in patients treated with either doses of alogliptin (OR = 2.4; 95% CI, 1.66 to 3.57 for 12.5 mg; OR = 2.4; 95% CI, 1.89 to 3.10 for 25 mg ). Similarly, when both doses compared separately with controls, the proportions of patients with ≥1% reduction of HbA1c from baseline were also significantly higher with alogliptin treated than controls (OR = 2.6; 95% CI, 1.83 to 3.56 for 12.5 mg; OR = 3.3; 95% CI, 2.54 to 4.28 for 25 mg).
The pooled SMD in alogliptin 12.5 mg treated vs controls and alogliptin 25 mg treated vs controls also showed a statistically significant reduction in FPG level among patients treated with either dose of alogliptin (SMD = −0.43, 95% CI = −0.6 to −0.26; SMD = −0.51, 95% CI = −0.68 to −0.34 for alogliptin 12.5 mg and alogliptin 25 mg, respectively). The heterogeneity test still showed a significant variation among the included studies (Figure 4). Sensitivity analysis showed that the SMD changed by about 0.05 at maximum with the withdrawal of any of the included study but no improvement of heterogeneity.
Figure 4. Standardize mean difference of the change in FPG level from a subgroup analysis based on study location, Alogliptin 25 mg vs Control, 2012.
The findings from the analysis of change in body weight in alogliptin 25 mg vs controls illustrated no difference. However, with moderate heterogeneity, the analysis of alogliptin 12.5 mg vs control showed a significant weight increment among the alogliptin 12.5 mg treated patients (SMD = 0.20; 95% CI, 0.06 to 0.33) (Figure 5).
Figure 5. Standardize mean difference of change in body weight, Alogliptin 12.5 mg vs Control, 2012.
Comparisons based on the number of patients who discontinued treatment due to adverse events in alogliptin 12.5 mg vs controls and alogliptin 25 mg vs controls were not significantly different. In other words, the number of patients who discontinued due to adverse events in the alogliptin treated group were not different from placebo or other antidiabetic drug treated (OR = 0.83; 95% CI, 0.61 to 1.58 for alogliptin 12.5 mg; and OR=0.98; 95% CI, 0.44 to 1.58 for alogliptin 25 mg (Figure 6).
Figure 6. Mantel-Haenszel odds ratio of patients who discontinued the treatment due to adverse events, Alogliptin 25 mg vs Control, 2012.
Similarly, as shown in Table 2, the proportion of patients who experienced adverse events or infections (skin or subcutaneous adverse events, headache, arthralgia, nasopharyngitis, diarrhoea, peripheral oedema, gastrointestinal adverse events, urinary tract infection, upper respiratory tract infection, infection and infestation, bronchitis, influenza, hypoglycaemia, and hypertension) were not significantly different from controls. Furthermore, the effect of either dose of alogliptin (12.5 mg and 25 mg) on serum lev of total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides was not also significantly different from controls (Table 3).
In agreement with a previous meta-analysis, that was conducted on DPP-4 inhibitors including four studies on alogliptin [27], this meta-analysis has demonstrated a significant reduction of HbA1c and FPG in patients treated with either alogliptin 12.5 mg or alogliptin 25 mg. Moreover, addition of either dose of alogliptin to a previously prescribed antidiabetic drug(s), in patients with inadequately controlled type 2 diabetes, has shown a statistically significant reduction in HbA1c and FPG - better than the previously prescribed antidiabetic drug(s) alone. Since the FPG reflects the hepatic glucose production, which depends on insulin secretory capacity of the pancreas [28], while the HbA1c provides information about the degree of long-term glycemic control [29], the finding of reduction in both markers with alogliptin probably indicates its short and long term efficacy.
Although heterogeneity testing showed a statistically significant dissimilarity in the results of the included studies, sensitivity analysis has shown the stability of the overall odds ratios with the withdrawal of any of the study from the analysis without a significant improvement of the heterogeneity. Thus, the credibility of the results of this meta-analysis did not seem compromised. This is because; when the number of included studies is small and heterogeneity is large, the robustness of the results is best assessed with a sensitivity analysis [30].
Meta-regression showed a negative relation between the duration of alogliptin therapy and its efficacy (HbA1c reduction become minimal). However, this does not necessarily mean that alogliptin is ineffective after 12 weeks of therapy. Rather, its long term efficacy needs further investigation. From the subgroup analysis, the effect of alogliptin add-on therapy (alogliptin plus other antidiabetic drug) in lowering HbA1c does not appear superior to alogliptin monotherapy. However, this finding should be interpreted very cautiously. This is because; two of the studies in the alogliptin monotherapy subgroup recruited patients with type 2 diabetes who were naïve to antidiabetic drugs [22,25]. As a result, patients with type 2 diabetes who were not antidiabetic drug experienced could probably respond better to alogliptin therapy. Additionally, prior study on a combination of other DPP-4 inhibitor (sitagliptin) with metformin has shown better glycemic control than DPP-4 inhibitor monotherapy [31].
On the other hand, the achievement of HbA1c ≤ 7% and HbA1c reduction by ≥ 1% brought further evidence in support of alogliptin efficacy in lowering elevated HbA1c. However, the reason for a significantly higher reduction of HbA1c in studies which were conducted in one country (all in Japan) than studies which were conducted in multiple countries is not exactly known. The possible explanation could be: 1) the shortness of the duration of therapies; i.e. unlike the other multi-country studies included in this meta-analysis (with a minimum duration of therapy 26 weeks), Japanese studies that were included in this meta-analysis have duration of therapy only 12 weeks. In support of this assumption, the meta-regression has shown more reduction in HbA1c in the 12 weeks therapy than the 26 weeks therapy. 2) The sample sizes of the studies which were conducted in Japan were relatively smaller than other studies which were conducted in multiple countries. It is known that small sample size studies have low power to establish the true research finding [32]. 3) There may be difference in ethnic and cultural background, which may have an influence on the treatment outcomes. Accordingly, Japanese patients with type2 diabetes could respond better to alogliptin than others. In support of our opinion, previous studies on other drugs have shown that there was difference between Japanese and Caucasians in pharmacokinetic and pharmacogenetic parameters for unknown reason [33,34].
This meta-analysis also showed a significant reduction in FPG level among alogliptin treated groups, that is a desirable effect of any antidiabetic drug. From the theorized causes of diabetes mellitus complications, the widely accepted is persistent hyperglycemia that leads to spontaneous glycosylation of amino acids, lipids and nucleic acid [35]. As a result, the major goals in the therapy of diabetes mellitus is to keep the plasma glucose level below 110 mg/dl and maintain HbA1c < 7% [36,37]. This meta-analysis demonstrated the efficacy of alogliptin even in poorly controlled diabetes with other antidiabetic drug(s). In other words, four of the included studies in FPG and five studies in the HbA1c analyses were conducted in patients who were on other antidiabetic drugs but with poorly controlled diabetes.
Patients with type 2 diabetes are usually overweight or obese [38]. Unluckily, some other antidiabetic drugs like sulfonylureas, meglitinides, thiazolidinediones and insulin are known to be associated with weight gain, and may aggravate the already gained weight [39,40]. However, the effect of alogliptin 25 mg on body weight was not different from the controls (placebo or other antidiabetic drug treated). But, the pooled analysis on body weight change among the alogliptin 12.5 mg treated group demonstrated a significant weight gain. The result should be considered with great caution and needs further investigation. This is because, previous meta-analysis on the effect of DPP-4 inhibitors on body weight showed that DPP-4 inhibitors were weight neutral agents [41].
Till proved otherwise, alogliptin is safe and effective in treating type 2 diabetes as add-on or monotherapy. The number of patients who discontinued their medication due to adverse events while receiving either doses of alogliptin was not different from the number patients who were receiving placebo or other antidiabetic drugs. Similarly, alogliptin treated patients with type 2 diabetes did not experience alogliptin related adverse events and there were no significant changes in serum lipids level. However, the authors of this meta-analysis share the concerns of other investigators on the possible adverse events of incretin-based therapies, such as pancreatitis, anaphylaxis and Steven Johnson's syndrome [42-45], which were not assessed in this meta-analysis due to lack of data.
As limitations, this meta-analysis has noted a high degree of heterogeneity among the included studies. The possible explanation for the inconsistencies across studies could be: the variation in the duration of therapies, the difference in the sites of the studies, the type of antidiabetic drugs used with alogliptin and for controls, patients' difference in their antidiabetic drug experience and the type of anidiabetic drugs used before the start of alogliptin therapy. Secondly, all the included studies were sponsored by a pharmaceutical company, in which the findings might ave been manipulated as noted by other authors [46,47]. Thirdly, since the included studies for meta-analyses of adverse events and change in serum lipids were few and these studies were not primarily designed to assess adverse events and lipid profile change, the findings might not be conclusive. This is because; sample sizes of the individual studies included in a meta-analysis did not provide adequate power to test rare adverse events [48]. Fourthly, this meta-analysis was not able to incorporate studies written in other languages.
In conclusion, regardless of the dose and antidiabetic drug treatment history, alogliptin alone or in combination with other antidiabetic drug(s) has significantly reduced HbA1c and FPG in patients with poorly controlled type 2 diabetes. Furthermore, the proportion of patients experiencing an adverse event, discontinuation due to adverse events, and the effect on serum lipids was not different from placebo or other antidiabetic drugs. However, the effect of alogliptin on body weight change and its consistent efficacy and safety for longer duration of therapy needs further investigation.
Competing interests
The authors declare that they have no competing interests.
Authors' contribution
AB conceived the study, conducted the literature search, performed the statistical analyses and participated in the study selection and manuscript writing. YB participated in articles selection, in manuscript writing and assisted in statistical analyses. Both authors read and approved the final manuscript.
We would like to thank WHO and publishers for setting up HINARI to enable us to access the full text of articles (included and excluded). Otherwise, we have not got any financial or technical support for this analysis.
Rosenstock J, Riddle MC: Insulin therapy in type 2 diabetes. In The CADRE handbook of diabetes management. Edited by Cefalu WT, Gerich JE, Leroith D. New York: Medical Information Press; 2004:145-168.
Chacra AR, Davidson JA, Diaz J, Escalante-Pulido M, Litwak LE, Mestman JH, More L, Violante RM: An algorithm for the treatment of type 2 diabetes in Latin America.
Diabetes Obes Metab 2005, 7:148-160. PubMed Abstract | Publisher Full Text
Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S: Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes.
Diabetes Care 2011, 34(Suppl2):S251-S257. PubMed Abstract | Publisher Full Text
Drucker DJ: The role of gut hormones in glucose homeostasis.
J Clin Invest 2007, 117:24-32. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase–4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
Clin Ther 2008, 30(3):499-512. PubMed Abstract | Publisher Full Text
Christopher R, Covington P, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A: Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase–4 inhibitor alogliptin in healthy male subjects.
Clin Ther 2008, 30(3):513-527. PubMed Abstract | Publisher Full Text
Wilmington N.C. PPD, Inc. (Nasdaq: PPDI):
PPD confirms Takeda receives NDA approval of NESINA® (alogliptin) from Japanese ministry of health, labour and welfare.
Available from: http://files.shareholder.com/downloads/PPDI/ebec798d14b9/PPDI.pdf webcite
Insight Pharma reports: executive summary.
Accessed in 2012. Available from: http://www.insightpharmareports.com/uploadedFiles/ExecutiveSummary webcite
Viereck C, Boudes P: An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Contemp Clin Trials 2011, 32(3):324-332. PubMed Abstract | Publisher Full Text
Choe C, Edelman S: New therapeutic options for treating type-2 diabetes: a review of insulin analogs and premixed insulin analogs.
J Natl Med Assoc 2007, 99(4):357-367. PubMed Abstract | PubMed Central Full Text
GooBen K, Gra¨ber S: Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
Conversion of units of glucose plasmatic level.
Accessed in 2012. Available from: http://en.mte.cz/conversion.php webcite
Rosenstock R, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q: Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without causing weight gain or increased hypoglycemia.
Diabetes Obes Metab 2009, 11:1145-1152.
Study 1PubMed Abstract | Publisher Full Text
Sterne JAC, Sutton AJ, Ioannidis JPA, Terrin N, Jones DR, Lau J, Carpenter J, Rücker G, Harbord RM, Schmid CH, Tetzlaff J, Deeks JJ, Peters J, Macaskill P, Schwarzer G, Duva S, Altman DG, Moher D, Higgins JP: Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.
BMJ 2011, 342:d4002. Publisher Full Text
Moher D, Liberati A, Tetzlaff J, Altman DG, and the PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
PLoS Med 2009, 6(7):e1000097.
Available from: http://medicine.plosjournals.org/ webcitePubMed Abstract | Publisher Full Text | PubMed Central Full Text
Review manager (RevMan) [computer program]. version 5.1. Copenhagen: the Nordic Cochrane centre, the Cochrane collaboration, 2011.
Available from http://ims.cochrane.org/revman webcite
Borenstein M, Hedges L, Higgins J, Rothstein H: Comprehensive meta-analysis version 2. Englewood NJ: Biostat; 2005.
Bosi E, Ellis GC, Wilson CA, Fleck PR: Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52 week, randomized, double-blind, active-controlled, parallel-group study.
Diabetes Obes Metab 2011, 13:1088-1096. PubMed Abstract | Publisher Full Text
Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q, and for the alogliptin Study 008 Group: Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomized, double-blind, placebo-controlled study.
Int J Clin Pract 2009, 63(1):46-55. PubMed Abstract | Publisher Full Text
Pratley RE, Reusch JEB, RWilson CA FP, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Curr Med Res Opin 2009, 25(10):2361-2371.
Study 1PubMed Abstract | Publisher Full Text
Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.
Diabetes Obes Metab 2009, 11:167-176.
Study 2PubMed Abstract | Publisher Full Text
Defronzo RA, Fleck PR, Wilson CA, Mekki Q: Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control.
Diabetes Care 2008, 31:2315-2317. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Rosenstock J, Inzucchi SE, Seufert J, Fleck PR, Wilson CA, Mekki Q: Initial combination therapy with alogliptin and pioglitazone in drug-naı¨ve patients with type 2 diabetes.
Diabetes Care 2010, 33:2406-2408.
Study 2PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y: Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
Diabetes Obes Metab 2011, 13:1028-1035. PubMed Abstract | Publisher Full Text
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K: Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
Curr Med Res Opin 2011, 9:1781-1792.
Study 1
Seino Y, Fujita T, Hiroi S, Hirayama M, Kaku K: Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
Curr Med Res Opin 2011, 27(S3):21-29.
Study 2PubMed Abstract | Publisher Full Text
Esposito R, Cozzolino D, Bellastella G, Maiorino MI, Chiodini P, Ceriello A, Giugliano D: Dipeptidyl peptidase-4 inhibitors and HbA1c target of < 7% in type 2 diabetes: Meta-analysis of randomized controlled trials.
Diabetes Obes Metab 2011, 13:594-603. PubMed Abstract | Publisher Full Text
Triplitt CL, Reasner CA, Isley WL: Diabetes mellitus. In Pharmacotherapy, a pathophysiologic approach. 6th edition. Edited by Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. New York: McGraw-Hill; 2005:1333-63.
Nathan DM, Singer DE, Hurxthal K, Goodson JD: The clinical information value of the glycosylated hemoglobin assay.
N Engl J Med 1984, 310:341-346. PubMed Abstract | Publisher Full Text
Fanelli D: How many scientists fabricate and falsify research? a systematic review and meta-analysis of survey data.
PLoS One 2009, 4(5):e5738. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE: Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
Diabetes Care 2007, 30:1979-1987. PubMed Abstract | Publisher Full Text
Ioannidis JPA: Why most published research findings are false.
PLoS Med 2005, 2(8):e124.
http://www.plosmedicine.org/article/info:doi/10.1371/ webcitePubMed Abstract | Publisher Full Text | PubMed Central Full Text
de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, Fukazawa I, van Doorn MBA, van den Heuvel MW, Machielsen CSM, Uchida E, Cohen AF: Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE).
Contraception 2003, 68:195-202. PubMed Abstract | Publisher Full Text
Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.
Clin Pharmacol Ther 2005, 78:330-41. PubMed Abstract | Publisher Full Text
Peppa M, Vlassara H: Advanced glycation end products and diabetic complications: a general overview.
Hormones 2005, 4(1):28-37. PubMed Abstract | Publisher Full Text
American Diabetes Association Treatment Algorithm for Type 2 Diabetes
Pharmacist's Letter/Prescriber's letter 2006, 22(11):221103.
http://faculty.ksu.edu.sa/mahaalrasheed/course/453_454/ADA_Diabetes_Treatment_Algorithm%202006.pdf webcitePubMed Abstract
Consumer reports health best buy drugs. The oral diabetes drugs: treating type 2 diabetes.
Available from: http://www.consumerreports.org/health/pdf/ webcite
Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JPH, Pinkney JH: Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors.
Postgrad Med J 2006, 82:280-284. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Mitri J, Hamdy O: Diabetes medications and body weight.
Expert Opin Drug Saf 2009, 8(5):573-584. PubMed Abstract | Publisher Full Text
Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach.
Diabetes Care 2012, 35:1364-1379. PubMed Abstract | Publisher Full Text
Monami M, Iacomelli I, Marchionni N, Mannucci E: Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.
Nutr Metab Cardiovas 2010, 20:224-235. Publisher Full Text
Rendell M, Drincic A, Andukuri R: Alogliptin benzoate for the treatment of type 2 diabetes.
Expert Opin Pharmacother 2012, 13(4):553-563. PubMed Abstract | Publisher Full Text
Andukuri R, Drincic A, Rendell M: Alogliptin: a new addition to the class of DPP-4 inhibitors.
Diabetes Metab Syndr Obes 2009, 2:117-126. PubMed Abstract | PubMed Central Full Text
Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC: Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies.
Gastroenterology 2011, 141(1):150-156. PubMed Abstract | Publisher Full Text
Olansky L: Do incretin-based therapies cause acute pancreatitis?
J Diabetes Sci Technol 2010, 4(1):228-229. PubMed Abstract | Publisher Full Text | PubMed Central Full Text
Chopra SS: Industry funding of clinical trials: benefit or bias?
JAMA 2003, 290(1):113-114. PubMed Abstract | Publisher Full Text
Doucet M, Sismondo S: Evaluating solutions to sponsorship bias.
J Med Ethics 2008, 34:627-630. PubMed Abstract | Publisher Full Text
Walker E, Hernandez AV, Kattan MW: Meta-analysis: its strengths and limitations.
Clev Clin J med 2008, 75(6):431-439. Publisher Full Text
Pre-publication history
The pre-publication history for this paper can be accessed here:


text:
Nigeria's Naira Advances Third Day on Oil Company Dollar Sales
Nigeria's naira strengthened for a third day as oil producers sold dollars to fund operations in the West African nation and after the government sold bills.
The currency of Africa's biggest oil producer advanced as much as 0.9 percent to 158.60 per dollar, the strongest level in more than a week, before trading 0.5 percent higher at 159.15 on the interbank market at 12:30 p.m. in Lagos, the commercial capital, according to data compiled by Bloomberg.
The naira has gained 0.7 percent this week, set for its second weekly advance, after the government sold 149.3 billion naira ($938 million) of three-, six- and 12-month bills. Lower demand for dollars by importers after cutbacks in fuel subsidies also buoyed the currency, according to the central bank.
"The stronger naira reflects a combination of factors, including foreign-exchange sales from oil companies as well as some inflows from offshore accounts to fund their T-bill purchases," Samir Gadio, an emerging markets strategist at Standard Bank Group Ltd. in London, said in an e-mailed reply to questions today.
President Goodluck Jonathan backtracked on an earlier decision to scrap a fuel subsidy in Nigeria after gasoline costs more than doubled, prompting protests and strikes. He has not reinstated the subsidy to levels that existed prior to the withdrawal, agreeing only to a partial reduction. Gasoline prices in Africa's most populous country surged by almost 50 percent last month, stoking inflation which touched 10.3 percent in December.
Moderating Demand
"We have seen a moderation in the demand for foreign exchange perhaps especially from the petroleum sector," central bank Deputy Governor Tunde Lemo told a public hearing of a House of Representatives committee investigating fuel subsidy discrepancies Feb. 7 in Abuja, the capital.
The nation's foreign-exchange reserves increased 5.5 percent this year to $34.7 billion as of Feb. 2, according to central bank data. Nigeria's central bank offers foreign currency to lenders at twice-weekly auctions and also sells dollars directly to banks through the interbank market by dipping into reserves, as it tries to keep the exchange rate around a midpoint of 155 naira per dollar and stabilize prices.
Ghana's cedi weakened 0.6 percent to 1.6979 per dollar, according to data compiled by Bloomberg.


text:
Enter your name and email to receive alerts when new vacation deals are added to any property in this region.
By clicking "Submit" you are agreeing to the
Terms of Service.
Alert successfully created!
Showing 1-1 of 1 Romantic Resorts
Finn'n Feather Resort
Find yourself relaxing in a secluded Minnesota cabin with your special someone. Cuddle up together in front of your own private fireplace and enjoy a glass of wine. Relax in the hot tub, or get out and enjoy the local dining options together. Most importantly, find the time to enjoy each other at this charming resort.... more
- Wifi
- Restaurant Onsite
- Pets Allowed
- Property Size 20 units
- Conference Facility
- Kids Allowed
- Nearby City Bemidji
- Nearby Water Lake Andrusia/Cass Lake chain
- Open Dates May 9 to Oct 6
- Beach
- Family
- Reunions
- Nature
- Fishing
- Romantic
- Lake
- Cabins, Cottages, and Chalets
Showing 1-1 of 1 Romantic Resorts


text:
Presidential Suite
The 2,100 square foot Presidential Suite is the crown jewel of our Penthouse Suites and the ultimate luxury experience. It comes complete with a 750 square foot sun deck, custom-built whirlpool tub, deck furniture for four, outdoor stereo system and a 180-Degree view of Monterey Bay. The living room is perfect for entertaining, with a fireplace, dining room table that seats 12, full bar with pantry, half bath and state-of-the-art entertainment center. The private bedroom offers unparalleled views of Monterey Bay, its own fireplace, oversized bathroom with double sink vanity, whirlpool bath tub and a separate shower and bidet.
Sort Order:


text:
Lakewood Link Recreation Center will be closed October 19-25 for maintenance. Fees for class sessions running at this time have been prorated to reflect classes missed that week.
The Gymnastics program is designed to expose youth to
the basics of gymnastics. This program provides a well-supervised, healthy and
safe environment for youth to experience the benefits of recreational
gymnastics and progress towards mastering skills on all apparatus and floor
tumbling. All classes occur at the Link Recreation Center.
For program
details and more information, explore the Quick Links to the
Walking to 6 years
$5 to drop in
and $45 for a 10 visit pass (*pass is also good for drop-in sports).
Gymnastics Classes
Gymnastics Team
CARA Lakewood Gold Stars(7-18 yrs.)
Visit www.caragymnastics.org
for more information also, explore the Quick Links for program details.
Middle School Cheerleading
Are you interested in becoming a coach or a volunteer?


text:
Already a Member? Log In
By clicking the button above, you agree to LoopNet's Terms of Use and Privacy Policy.
Copy the code above and use it on your web site.
You may enter a US or Canadian location in the following formats:
For additional search options, go to
Advanced Search
Advanced Search
Advanced Search
Advanced Search.
Browse More Listings in Office For Lease, Panama City, FL or Florida
Front View From Parking Area
"6 MONTHS FREE RENT" Constructed in 2006, Baldwin Medplex offers Executive Medical Office Space available for lease in the heart of Panama City. Baldwin Medplex is centrally located, offers high visibility, and easy access to both area hospitals and all major commercial highway arteries. This tastefully designed and decorated suite was formerly occupied by North Bay Imaging, and is the last remaining suite available at Baldwin Medplex. The suite is located at the buildings north endcap facing Baldwin Road with excellent visibility and signage. The suite consists of a large enty/reception area, large nurse work station with file/records area, 4 handi-cap restrooms, Sub-waiting room with 2 dressing rooms, 1 office, break room, hot lab, and 2 large MRI/CT/Pet Scan rooms with a middle monitoring room, all on the ground floor, and an additional 964± S.F. finished upstairs storage area (heated and cooled). The offered lease rate is $15.00 S.F NNN for the ground floor (3,608± S.F.) and $10.00 S.F. Gross for the upper floor (964± S.F.). Ready for immediate occupancy.
Located near the intersection of Baldwin Road and Highway 390, directly across from Peaden Air Conditioning and adjacent the Panama City/Bay County International Airport.
Media caption will be displayed here under the location
It apprears that there's a network issue. Please try sending the message again.
Email address already exists. Please log in and send the message again or use another email address.
There is an unknown exception.
By clicking "Contact Listing Broker", you are indicating that you have read, understood, and agree to LoopNet's Terms and Conditions.
New to LoopNet? No problem. As a courtesy, LoopNet will automatically create a free account so that you can access more listing details, setup new listing alerts, and more.
We will not share your email address. View our Privacy Policy.
Copy the code to embed this video on your website.


text:
Want to meet Taylor Swift? Of course you do and here is your chance. The country star is giving fans an opportunity to see her in concert and meet her, all while supporting a worthwhile cause.
Swift is giving anyone the chance to win four VIP tickets to her concert on Wed., July 20, 2011, in Newark, NJ.
All proceeds benefit the T.J. Martell Foundation, an organization supporting leukemia, cancer and AIDS research. Music industry executive, Tony Martell, founded the charity in1975 in loving memory of his son, T.J., who died of leukemia. So far, it has provided over $250 million dollars for research through events including concerts, gala award dinners, golf tournaments and walk-a-thons.
If you want to be the lucky one to support an awesome charity and meet the singing sensation, get on eBay before the auction ends on July 18.
About Allyson KoernerAllyson Koerner first found her love of writing while attending Westminster College in Pennsylvania, and that passion evolved while she was earning her Master's in Print & Multimedia Journalism at Boston's Emerson College. She's an experienced writer dabbling in all things vegan, green, entertainment and TV-related. Feel free to keep tabs on her over at Twitter: @AllysonKoerner.
View all posts by Allyson Koerner →


text:
1099 New York Avenue, NW
Suite 520
Washington, DC 20001
August 13, 2010
Smart Grid Issues Discussed at TPI Aspen Forum
Breakout Session to Feature Experts on Electricity Regulation
For Immediate Release
Contact: Amy Smorodin
The increased use of electronics in our daily lives has strained America's electricity infrastructure. Can Smart Grid technologies and the modernization of the power infrastructure keep up with the increased demand for energy? Are incentives and other programs helping at the state and federal levels? Is "Smart Grid" a prudent investment that will benefit consumers, or an expensive boondoggle fraught with standards, control and gold plating issues? The Technology Policy Institute Aspen Forum will feature a breakout session on Smart Grid technologies, their implementation, and related issues for utility regulators. The session is one of three off-the-record discussions scheduled at the Forum, to be held August 22 - 24 at the St. Regis in Aspen, Colorado.
Speakers scheduled for the session include:
Kathy Brown, Senior Vice President for Public Policy Development and Corporate Responsibility, Verizon
Jeff Campbell, Senior Director, Technology and Trade Policy of Global Policy and Government Affairs, Cisco
Sherman Elliott, Commissioner, Illinois Commerce Commission
Patrick J. McCormick III, Partner, Hunton & Williams LLP
Nick Sinai, Energy and Environment Director, Omnibus Broadband Initiative, Federal Communications Commission
The session will be moderated by Raymond Gifford, Partner at Wilkinson Barker Knauer, LLP and member of the Board at the Technology Policy Institute.
TPI's Aspen Forum will bring together notable representatives from business, government, and academia in a relaxed, informal setting to discuss and debate the key public policy issues surrounding information and communications technology. Other top leaders from the technology and policy sectors scheduled to speak at the Forum include Paul Otellini of Intel Corporation, Mark McLaughlin of VeriSign, Brad Smith of Intuit, Reid Hoffman of LinkedIn and Greylock Partners, Thomas Tauke of Verizon, Joe Waz of Comcast, and author Andrew Keen. Edward Mueller of Qwest Communications will offer opening remarks at the premier policy event. An updated agenda can be found here.
To register, please visit www.techpolicyinstitute.org/aspen2010. For additional information, please contact Jane Creel at firstname.lastname@example.com. Members of the press can contact Amy Smorodin at firstname.lastname@example.com.
The Technology Policy Institute
The Technology Policy Institute is a research and educational organization that focuses on the economics of innovation, technological change, and related regulation in the United States and around the world. More information is available at http://www.techpolicyinstitute.org/


text:
Welcome to WebmasterWorld Guest from 22.214.171.124
Moderators: open
I wonder if using Google Public DNS [code.google.com] would cause that? Do you know if you're using their DNS service instead of the one your ISP provides?
is your system clean? You may want to check the active connections of your system also.
Become a Pro Member